Ignite Creation Date:
2024-05-06 @ 4:24 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04977089
Status:
UNKNOWN
Last Update Posted:
2021-07-26
First Post:
2021-07-14
Brief Title:
Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital
Status:
UNKNOWN
Status Verified Date:
2021-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic coronary syndrome CCS is a newly described classification devised by the European Society of Cardiology ESC 2019 to replace the term Stable Coronary Artery Disease CAD
The main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical pharmacological and pathophysiological entities
Using this new term the disease atherosclerosis manifests as CAD is categorized into Acute Coronary Syndrome ACS and CCS
The main focus of introducing the concept of CCS is on the fact that CAD is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases
Dyslipidemia is recognized as a prominent risk factor for cardiovascular CV disease
It is characterized by an elevation of serum total cholesterol TC low-density lipoprotein cholesterol LDL-C or triglycerides TG and reduced serum high-density lipoprotein cholesterol HDL-C concentration
Genetically determined and metabolically induced disturbances in lipid metabolism as manifested in several types of dyslipidemia have been shown to be causally related to the development of coronary artery disease CAD
A diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events
Independent predictors of recurrent CVD events or death include age smoking hypertension HTN dyslipidemia diabetes mellitus chronic kidney disease and the underutilization of medications recommended by current treatment guidelines
The main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical pharmacological and pathophysiological entities
Using this new term the disease atherosclerosis manifests as CAD is categorized into Acute Coronary Syndrome ACS and CCS
The main focus of introducing the concept of CCS is on the fact that CAD is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases
Dyslipidemia is recognized as a prominent risk factor for cardiovascular CV disease
It is characterized by an elevation of serum total cholesterol TC low-density lipoprotein cholesterol LDL-C or triglycerides TG and reduced serum high-density lipoprotein cholesterol HDL-C concentration
Genetically determined and metabolically induced disturbances in lipid metabolism as manifested in several types of dyslipidemia have been shown to be causally related to the development of coronary artery disease CAD
A diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events
Independent predictors of recurrent CVD events or death include age smoking hypertension HTN dyslipidemia diabetes mellitus chronic kidney disease and the underutilization of medications recommended by current treatment guidelines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None